Sage Therapeutics to Present at Morgan Stanley 16th Annual Global Healthcare Conference
September 06 2018 - 4:05PM
Business Wire
Sage Therapeutics (NASDAQ: SAGE), a clinical-stage
biopharmaceutical company developing novel medicines to treat
life-altering central nervous system (CNS) disorders, today
announced that the Company will present at the Morgan Stanley 16th
Annual Global Healthcare Conference on Wednesday, September
12, 2018 at 01:40 P.M. ET in New York, NY.
A live webcast of the presentation can be accessed on the
investor page of Sage's website at investor.sagerx.com. A replay of
the webcast will also be archived for up to 30 days on Sage's
website following the conference.
About Sage Therapeutics
Sage Therapeutics is a clinical-stage biopharmaceutical company
committed to developing novel medicines to transform the lives of
patients with life-altering CNS disorders. Sage's lead product
candidate, ZULRESSO™ (brexanolone injection), has completed Phase 3
clinical development for postpartum depression and a New Drug
Application is currently under review with the U.S. Food and Drug
Administration. Sage is developing a portfolio of novel product
candidates targeting critical CNS receptor systems, including
SAGE-217, which is in Phase 3 development in major depressive
disorder and postpartum depression. For more information, please
visit www.sagerx.com.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20180906005905/en/
Sage TherapeuticsInvestor Contact:Paul Cox,
617-299-8377paul.cox@sagerx.comorMedia Contact:Jeff Boyle,
617-949-4256jeff.boyle@sagerx.com
Sage Therapeutics (NASDAQ:SAGE)
Historical Stock Chart
From Mar 2024 to Apr 2024
Sage Therapeutics (NASDAQ:SAGE)
Historical Stock Chart
From Apr 2023 to Apr 2024